Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹297.85
13.95 (4.91%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹1.04K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
15.0
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹161.5+84.4%
52W High₹315.2-5.5%
Current Price
₹297.85
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹238.28
Upper Circuit₹357.42
Reference Price
₹297.85
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹326.4
Inverse Head and Shoulders on 1D (BREAKOUT CONFIRMED) — target ₹336.4
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 45.15 (BUY) with 52.8% confidence
SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
53%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
278.84
EMA50
270.47
EMA200
257.57
Price Action
MIXED
NEUTRAL
Higher Highs4
Higher Lows5
Lower Highs5
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹299.00
₹309.00
₹315.20
Support (Below)
₹285.39
₹278.62
₹274.20
₹266.50
₹259.15
Volume Analysis
TrendSTABLE
Change+0.90%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹294.87
3% Risk₹288.91
5% Risk₹282.96
7% Risk (Custom)
₹277.00Technical Levels
1x ATR (Volatility)₹282.81
2x ATR (Swing)₹267.77
3x ATR (Trend)₹252.73
Immediate Support₹285.39
Moving Averages
EMA 9 (Short-term)₹283.56
EMA 20 (Medium-term)₹278.84
EMA 50 (Trend)₹270.47
EMA 200 (Long-term)₹257.57
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹172 Cr | ₹163.2 Cr | ₹160.1 Cr | ₹162.4 Cr |
| Net Profit | ₹20.3 Cr | ₹13.5 Cr | ₹15.2 Cr | ₹15.8 Cr |
| EPS | — | ₹4.12 | ₹4.58 | ₹4.52 |
| Operating Profit | ₹31.5 Cr | ₹24.8 Cr | ₹26 Cr | ₹26.9 Cr |
ROE
51.51%
ROCE
28.16%
Debt/Equity
2.98
Current Ratio
1.11
OPM
16.54%
NPM
9.70%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Wanbury Limited | ₹297.85 | +4.91% | 15.0 | ₹1.04K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 20 Sept 2024 | Annual General Meeting | AGM |
| 10 Nov 2023 | Extra Ordinary General Meeting | OTHERS |
| 20 Sept 2023 | Annual General Meeting | AGM |
| 14 Aug 2023 | Extra-Ordinary General Meeting | OTHERS |
| 20 Sept 2022 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for WANBURY
View AllNEWS
positive
Business Standard - Markets 31d ago
Wanbury explores new market opportunities for its new APIs
Receives Korea FDA approval for its Patalganga facility
WANBURYHealthcare
NEWS
neutral
Business Standard - Markets 40d ago
Wanbury standalone net profit rises 7.11% in the March 2026 quarter
Sales decline 4.31% to Rs 164.58 crore
WANBURYHealthcare